123 related articles for article (PubMed ID: 15935659)
1. Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.
Hattori K; Takamura F; Tanaka A; Takasugi H; Taniguchi K; Nishio M; Koyama S; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jul; 15(13):3284-7. PubMed ID: 15935659
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2.
Hattori K; Okitsu O; Tabuchi S; Taniguchi K; Nishio M; Koyama S; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jul; 15(13):3279-83. PubMed ID: 15935660
[TBL] [Abstract][Full Text] [Related]
3. Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.
Hattori K; Tanaka A; Okitsu O; Tabuchi S; Taniguchi K; Nishio M; Koyama S; Higaki M; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jun; 15(12):3091-5. PubMed ID: 15914004
[TBL] [Abstract][Full Text] [Related]
4. Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.
Tanaka A; Hattori K; Taniguchi K; Okitsu O; Tabuchi S; Nishio M; Nagakura Y; Maeda N; Murai H; Seki J
Bioorg Med Chem Lett; 2006 Sep; 16(18):4861-4. PubMed ID: 16837197
[TBL] [Abstract][Full Text] [Related]
5. Metabolism investigation leading to novel drug design 2: orally active prostacyclin mimetics. Part 5.
Takamura F; Tanaka A; Takasugi H; Taniguchi K; Nishio M; Seki J; Hattori K
Bioorg Med Chem Lett; 2006 Sep; 16(17):4475-8. PubMed ID: 16824754
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
7. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon.
Rudd JA; Qian Ym; Tsui KK; Jones RL
Br J Pharmacol; 2000 Feb; 129(4):782-90. PubMed ID: 10683203
[TBL] [Abstract][Full Text] [Related]
8. Discovery and preliminary evaluation of 5-(4-phenylbenzyl)oxazole-4-carboxamides as prostacyclin receptor antagonists.
Brescia MR; Rokosz LL; Cole AG; Stauffer TM; Lehrach JM; Auld DS; Henderson I; Webb ML
Bioorg Med Chem Lett; 2007 Mar; 17(5):1211-5. PubMed ID: 17239589
[TBL] [Abstract][Full Text] [Related]
9. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
10. Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.
Hattori K; Tanaka A; Fujii N; Takasugi H; Tenda Y; Tomita M; Nakazato S; Nakano K; Kato Y; Kono Y; Murai H; Sakane K
J Med Chem; 2005 May; 48(9):3103-6. PubMed ID: 15857112
[TBL] [Abstract][Full Text] [Related]
11. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750
[TBL] [Abstract][Full Text] [Related]
13. Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Trehan AK; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS
Drug Des Discov; 1994 Jan; 11(1):73-89. PubMed ID: 7520762
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
Polla MO; Tottie L; Nordén C; Linschoten M; Müsil D; Trumpp-Kallmeyer S; Aukrust IR; Ringom R; Holm KH; Neset SM; Sandberg M; Thurmond J; Yu P; Hategan G; Anderson H
Bioorg Med Chem; 2004 Mar; 12(5):1151-75. PubMed ID: 14980627
[TBL] [Abstract][Full Text] [Related]
15. 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.
Sandham DA; Adcock C; Bala K; Barker L; Brown Z; Dubois G; Budd D; Cox B; Fairhurst RA; Furegati M; Leblanc C; Manini J; Profit R; Reilly J; Stringer R; Schmidt A; Turner KL; Watson SJ; Willis J; Williams G; Wilson C
Bioorg Med Chem Lett; 2009 Aug; 19(16):4794-8. PubMed ID: 19592244
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
Kawai M; Nakamura H; Sakurada I; Shimokawa H; Tanaka H; Matsumizu M; Ando K; Hattori K; Ohta A; Nukui S; Omura A; Kawamura M
Bioorg Med Chem Lett; 2007 Oct; 17(20):5533-6. PubMed ID: 17768047
[TBL] [Abstract][Full Text] [Related]
17. A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic.
Hattori K; Tabuchi S; Okitsu O; Taniguchi K
Bioorg Med Chem Lett; 2003 Dec; 13(24):4277-9. PubMed ID: 14643308
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
Crosignani S; Page P; Missotten M; Colovray V; Cleva C; Arrighi JF; Atherall J; Macritchie J; Martin T; Humbert Y; Gaudet M; Pupowicz D; Maio M; Pittet PA; Golzio L; Giachetti C; Rocha C; Bernardinelli G; Filinchuk Y; Scheer A; Schwarz MK; Chollet A
J Med Chem; 2008 Apr; 51(7):2227-43. PubMed ID: 18318469
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
[TBL] [Abstract][Full Text] [Related]
20. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
